“…In spite of the development of new drugs, such as new azole or echinocandin derivatives, there has been a dramatic increase in both anti-Candida resistance and the frequency of invasive Candida infections (Pfaller, 2012). Among enormous classes of heterocyclic compounds, the synthesis of new derivatives of 1,2,4-triazole-3-thiones and 2-amino-1,3,4-thiadiazoles has been attracting considerable attention because of their broad biological activity, including antibacterial and antifungal (Güzeldemirci, Küçükbasmaci, 2010;Plec et al, 2011;Camoutsis et al, 2010;Küçükgüzel et al, 2007;Kadi et al, 2007), anti-tubercular (Küçükgüzel et al, 2001;Küçükgüzel et al, 2008), antiviral (Abdel-Aal et al, 2003;Küçükgüzel et al, 2008), antioxidant (Ayhan-Kilcigil et al, 2004;Khan et al, 2010), antitumoral Rzeski, Matysiak, Kandefer-Szerszen, 2007;Mavrova et al, 2009), anti-inflammatory (Amir, Shikha, 2004;Kadi et al, 2007;Küçükgüzel et al, 2007;Kumar et al, 2008), and anticonvulsant activity (Kane et al, 1994;Sharma et al, 2011;Dogan et al, 2002). Clinically-used antifungal azole drugs containing either an imidazole (e.g., econazole, miconazole, clotrimazole, and ketoconazole) or a 1,2,4-triazole moiety (e.g., fluconazole and itraconazole) have a high therapeutic index and significant safety profile (Wang et al, 2009).…”